Regulatory effects of resveratrol on glucose metabolism and T-lymphocyte subsets in the development of high-fat diet-induced obesity in C57BL/6 mice

Wang, Bin; Sun, Jin; Li, Longnan; Zheng, Jing; Shi, Yonghui; Li, Guowei

doi:10.1039/c3fo60714c

Cited by 36 publications

(39 citation statements)

References 66 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Lagouge et al [30] show that RSV (200 or 400 mg/kg/day) significantly attenuates weight gain and protects mice against diet-induced obesity. Furthermore, RSV treatment for 26 weeks significantly decreases body weight and high-fat diet-induced obesity in C57BL/6 mice [31]. In this study, treatment time for RSV is 8 weeks and the dose is 20 μmol/L.…”

Section: Discussionmentioning

confidence: 99%

Resveratrol ameliorates diet-induced dysregulation of lipid metabolism in zebrafish (Danio rerio)

Ran

Lin

et al. 2017

PLoS ONE

View full text Add to dashboard Cite

Defective lipid metabolism is associated with increased risk of various chronic diseases, such as obesity, cardiovascular diseases, and diabetes. Resveratrol (RSV), a natural polyphenol, has been shown the potential of ameliorating disregulations of lipid metabolism. The objective of this study was to investigate the effects of feed intake and RSV on lipid metabolism in zebrafish (Danio rerio). The adult males were randomly allocated to 6 groups: control (Con, 8 mg cysts/fish/day), control with 20 μmol/L RSV (Con+RSV), calorie restriction (CR, 5 mg cysts/fish/day), calorie restriction with RSV (CR+RSV), overfeed (OF, 60 mg cysts/fish/day), and overfeed with RSV (OF+RSV) groups. The treatment period was 8 weeks. Results showed that CR reduced body length, body weight, and condition factor of zebrafish. CR reduced levels of plasma triglyceride (TG) and induced protein expression of phosphorylated AMP-activated protein kinase-α (pAMPKα), silent information regulator 2 homolog 1 (Sirt1), and peroxisome proliferator activated receptor gamma coactivator-1α (PGC1α). RSV attenuated CR-induced pAMPKα/AMPKαincreases. RSV increased levels of Sirt1 protein in the OF zebrafish, and decreased OF-induced increase in peroxisome proliferator-activated receptor-γ (PPARγ) protein level. Additionally, RSV down-regulated caveolin-1 and up-regulated microtubule-associated protein 1 light chain 3 -II (LC3-II) protein levels in OF zebrafish. In conclusion, these results suggest that 1) CR reduces plasma TG level through activation of the AMPKα-Sirt1- PGC1α pathway; 2) under different dietary stress conditions RSV might regulate AMPK phosphorylation bi-directionally; 3) RSV might regulate lipid metabolism through the AMPKα-Sirt1-PPARγ pathway in OF zebrafish.

show abstract

Section: Discussionmentioning

confidence: 99%

Resveratrol ameliorates diet-induced dysregulation of lipid metabolism in zebrafish (Danio rerio)

Ran

Lin

et al. 2017

PLoS ONE

View full text Add to dashboard Cite

show abstract

“…Obesity has become a severe health issue globally. Resveratrol significantly decreased the body weight and fat mass in mice with HFD-induced obesity, showing reduced leptin and lipids in plasma, modulated metabolism of glucose and insulin, and restored immune dysfunction, via the activation of PI3K/SIRT1 and Nrf2 signaling pathways, and the inhibition of transcriptional regulators (e.g., EP300 gene), which are involved in the differentiation of adipocytes as well as lipid storage and metabolism [95,96]. Moreover, besides a significant dose-dependent decrease of weight gain and lipid deposition in the liver and adipose tissues of HFD-induced obese mice, low concentrations of resveratrol (1-10 µM) suppressed adipogenic differentiation in pre-adipocytes, downregulated the expression of peroxisome proliferator-activated receptor γ (PPAR-γ) and perilipin protein in differentiated adipocytes, and inhibited TNF-α-induced lipolysis in mature adipocytes [97].…”

Section: Obesitymentioning

confidence: 99%

Health Benefits and Molecular Mechanisms of Resveratrol: A Narrative Review

Meng

Zhou

Zhao

et al. 2020

Foods

232

144

View full text Add to dashboard Cite

Resveratrol is a bioactive compound in many foods. Since its anticancer activity was reported in 1997, its health benefits have been intensively investigated. Resveratrol has antioxidant, anti-inflammatory, immunomodulatory, glucose and lipid regulatory, neuroprotective, and cardiovascular protective effects, therefore, can protect against diverse chronic diseases, such as cardiovascular diseases (CVDs), cancer, liver diseases, obesity, diabetes, Alzheimer's disease, and Parkinson's disease. This review summarizes the main findings of resveratrol-related health benefits in recent epidemiological surveys, experimental studies, and clinical trials, highlighting its related molecular mechanisms. Resveratrol, therefore, has been regarded as a potent candidate for the development of nutraceuticals and pharmaceuticals to prevent and treat certain chronic diseases. Foods 2020, 9, 340 Iranian (Tehranian)/Iran Cross-sectional study, part of the TLG study N = 2618 (male, 1162; female, 1456) Quartiles: Q1: 0.014 mg/day Q2: 0.015-0.027 mg/day Q3: 0.028-0.053 mg/day Q4: 0.054 mg/day (FFQ on a daily frequency, 1 year prior) Null: Significantly associated with WC, TG, HDL, BG, and MS Unfavorable: The top quantile of intake (0.054 mg/day and more) was positively associated with high BP (HR = 1.52; 95% CI: 1.02-2.27) [19] Spanish/Spain Cross-sectional study, part of the PREDIMED study N = 1000 (male, 479; female, 521) Quintiles: Q1: 0.48 mg/day Q2: 1.04 mg/day Q3: 2.04 mg/day Q4: 5.75 mg/day (FFQ, 1 year prior) Favorable: Significantly decreased CVD risk factors (FBG (95% CI: −1.033 to −0.033); TG (95% CI: −1.998 to −0.029); and heart rate (95% CI: −0.467 to −0.087)). Null: Resveratrol intake was not significantly associated with TC, HDL, LDL and BP [6] Spanish/Spain Cross-sectional study, part of the PREDIMED study N = 7172 (male, 3249; female, 3923) Quintiles: Q1: 0.48 mg/d Q2: 1.04 mg/d Q3: 2.04 mg/day Q4: 5.75 mg/day (FFQ, 1 year prior) Favorable: High dose intake (5.75 mg/d) significantly reduced all-cause mortality by 52% (HR = 0.48; 95% CI: 0.25-0.91) Null: No significant CVD risk reduction (HR = 0.77; 95% CI: 0.35-1.72) [21,22] Swedish/Sweden Case-control study N = 1400 (case, 594 including (OAC, 181; OSCC, 158; JAC, 255)) (control, 806) Control: 0.1 mg/day OAC: 0.07 mg/day OSCC: 0.11 mg/day JAC: 0.09 mg/day (FFQ, 20 years prior) Favorable: In a significantly negative association with the risk of 3 subtypes of esophageal cancer (OAC (95% CI: 0.12-0.49); OSCC (95% CI: 0.15-0.65), and JAC (95% CI: 0.28-0.84)) [5] Italian/Italy Cohort study, "Aging in the Chianti Region" N = 529 (male, 236; female, 293) Tertiles: T1: 0.1 mg/day T2: 0.1-1.1 mg/day T3: >1.1 mg/day (FFQ) Favorable: Inversely associated with the risk of frailty syndrome during the first 3-year follow-up (T3 vs. T1: OR = 0.11; 95% CI: 0.03-0.45) Null: No substantial association with (i) risk of frailty syndrome in 6-, or 9-year follow-up; (ii) inflammatory biomarkers including IL-6, IL-1β, TNF-α, and CRP; (iii) CVD, cancer or all-cause mortality [18] Chinese/Chin...

show abstract

“…However, results from animal and human studies on the anti‐obesogenic actions of resveratrol are conflicting. Resveratrol decreased body weight and fat mass in rodent models including high‐fat diet‐induced obesity (0.06% in diet for up to 26 weeks or 30 mg kg −1 d −1 for 60 d or 0.02% in diet for 10 weeks) , apoE‐deficient mice (0.02% dietary for 12 weeks), db / db mice (0.005% and 0.02% dietary for 10 weeks) , obese rats programmed by maternal high‐fat diet (30 mg kg −1 d −1 for 8 weeks) , obese rats programmed by early weaning (30 mg kg −1 d −1 for 30 d) , Otsuka Long‐Evans Tokushima fatty rats (0.5% for 4 weeks) , fructose‐fed rats (10 mg kg −1 d −1 for 8 weeks) and Zucker fatty rats (15 or 45 mg kg −1 d −1 for 6 weeks) . Resveratrol‐enriched genetically modified rice reduced the body weight and abdominal fat volumes in mice fed a high‐fat diet .…”

Section: Stilbenes: Resveratrol and Pterostilbenementioning

confidence: 99%

Functional foods as potential therapeutic options for metabolic syndrome

2015

View full text Add to dashboard Cite

Obesity as part of metabolic syndrome is a major lifestyle disorder throughout the world. Current drug treatments for obesity produce small and usually unsustainable decreases in body weight with the risk of major adverse effects. Surgery has been the only treatment producing successful long-term weight loss. As a different but complementary approach, lifestyle modification including the use of functional foods could produce a reliable decrease in obesity with decreased comorbidities. Functional foods may include fruits such as berries, vegetables, fibre-enriched grains and beverages such as tea and coffee. Although health improvements continue to be reported for these functional foods in rodent studies, further evidence showing the translation of these results into humans is required. Thus, the concept that these fruits and vegetables will act as functional foods in humans to reduce obesity and thereby improve health remains intuitive and possible rather than proven.

show abstract

Regulatory effects of resveratrol on glucose metabolism and T-lymphocyte subsets in the development of high-fat diet-induced obesity in C57BL/6 mice

Cited by 36 publications

References 66 publications

Resveratrol ameliorates diet-induced dysregulation of lipid metabolism in zebrafish (Danio rerio)

Resveratrol ameliorates diet-induced dysregulation of lipid metabolism in zebrafish (Danio rerio)

Health Benefits and Molecular Mechanisms of Resveratrol: A Narrative Review

Functional foods as potential therapeutic options for metabolic syndrome

Contact Info

Product

Resources

About